Catherine C. Turkel is President at Novus Therapeutics, Inc. (NVUS). They have made 6 open-market trades across 2 companies since 2017, most recently 2024-08-12.
CIK 0001705278
5 open-market purchases totalling $557K since 2017, against 1 sale. Across 5 scored buys the stock is down 43.9% at ninety days, and 44.7 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 20% | 0% |
| Avg Move | +0.2% | -6.8% | -43.9% |
| Alpha | -0.5% | -6.7% | -44.7% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LEXX | BUY | 2024-08-12 | 2024-08-13 | $3.13 | $5K | -5.6% | +9.7% | -28.0% |
| LEXX | BUY | 2023-02-09 | 2023-02-27 | $2.84 | $4K | +6.2% | -9.8% | -75.6% |
| NVUS | SELL | 2019-05-20 | 2019-05-22 | $1.95 | $19K | -9.9% | -42.7% | -57.9% |
| NVUS | BUY | 2018-09-11 | 2018-09-13 | $4.79 | $322K | -4.5% | -16.8% | -47.5% |
| NVUS | BUY | 2018-09-05 | 2018-09-07 | $3.97 | $3K | +13.8% | -4.2% | -31.9% |
| NVUS | BUY | 2017-05-10 | 2017-05-11 | $9.99 | $222K | -9.0% | -12.5% | -36.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.